Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TripleTRE trial of initial triple versus double therapy in pulmonary arterial hypertension
NL-OMON61116Phase 4Not yet recruiting
- Sponsor
- AOP Health
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by AOP Health. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON61116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61116.